| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/18/2009 | EP2023895A2 Pharmaceutical compositions for vein irritating drugs |
| 02/18/2009 | EP1809267B1 Pharmaceutical compositions based on nk2 antagonists for pediatric use |
| 02/18/2009 | EP1725578B1 A novel potassium channel modulator peptide |
| 02/18/2009 | EP1682167B1 Use of hyperpolymer haemoglobin for treating a pulmonary oedema |
| 02/18/2009 | EP1679372B1 Novel plexin polypeptide, dna encoding the same and use thereof |
| 02/18/2009 | EP1629000B1 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| 02/18/2009 | EP1576368B1 Methods and compositions for enhancing fibrocyte formation |
| 02/18/2009 | EP1569958B1 Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-c5 amino acid segment and a non-self amino acid segment |
| 02/18/2009 | EP1562630A4 Injectible bioadhesive polymeric hydrogels as well as related methods of enzymatic preparation |
| 02/18/2009 | EP1501530B1 Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma |
| 02/18/2009 | EP1458757B1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor |
| 02/18/2009 | EP1448281B1 Therapeutic coating for an intravascular implant |
| 02/18/2009 | EP1434884B1 Single nucleotide polymorphisms predicting cardiovascular disease |
| 02/18/2009 | EP1366063B1 Inhibitors of lyn-associated signal transduction (last) and the use thereof in the treatment of prostate cancer |
| 02/18/2009 | EP1346034B1 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE |
| 02/18/2009 | EP1329503B1 Sphingolipid ceramide deacylase gene |
| 02/18/2009 | EP1140157B1 Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| 02/18/2009 | EP1135467B1 Psca: prostate stem cell antigen and uses thereof |
| 02/18/2009 | EP1084137B1 Peptide inhibitors of hepatitis c virus ns3 protease |
| 02/18/2009 | EP1071955B2 Improved immunodiagnostic assays using reducing agents |
| 02/18/2009 | EP1027063B1 Mannose receptor bearing cell line and antigen composition |
| 02/18/2009 | EP1021167B1 High and low load formulations of igf-i in multivesicular liposomes |
| 02/18/2009 | EP0969866B2 Immunotherapy of b-cell malignancies using anti-cd22 antibodies |
| 02/18/2009 | EP0922761B1 Monoclonal antibody specific to anti-human fibrin monomer, process for producing the same, hybridomas, and immunoassay method |
| 02/18/2009 | CN101370825A Novel FSH glycosylation variant D3N |
| 02/18/2009 | CN101370524A Lipopeptide compositions |
| 02/18/2009 | CN101370522A Specific therapy using integrin ligands for treating cancer |
| 02/18/2009 | CN101370519A Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer |
| 02/18/2009 | CN101370512A Isolated organ perfusion combination therapy of cancer |
| 02/18/2009 | CN101370511A Activin-ActRlla antagonists and uses for promoting bone growth |
| 02/18/2009 | CN101370510A Anticancer agent comprising a peptide |
| 02/18/2009 | CN101370509A Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer |
| 02/18/2009 | CN101368176A Complex phospho-esterase, extraction method and complex phospho-esterase capsule |
| 02/18/2009 | CN101367877A Monkey monoclonal antibodies specific to human B7.1 and/or B7.2 primatized forms, pharmaceutical compositions |
| 02/18/2009 | CN101367873A Modified glucagon sample peptide-1analogue and modifying matter, and uses thereof |
| 02/18/2009 | CN101367872A Protein-polymer conjugates |
| 02/18/2009 | CN101367871A Snake venom protein component of ahylysantinfarctase at southern Anhui Province, extraction method and uses thereof |
| 02/18/2009 | CN101367869A Polypeptide for preventing, diagnosing and treating hepatitis E virus, and vaccine as diagnosis agent of the same |
| 02/18/2009 | CN101367834A Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| 02/18/2009 | CN101366949A Method for improving feed efficiency and/or growth rate and/or fat reduction of livestock |
| 02/18/2009 | CN101366946A Starch based segmented intestine targeting specific adhesion material, preparation and application thereof |
| 02/18/2009 | CN101366944A Uses of MRPINK in restraining liveness of Macrobracium rosenbergii spermatozoon |
| 02/18/2009 | CN101366943A Hemoglobin polypeptide aminophenol nutrient and preparation method thereof |
| 02/18/2009 | CN101366736A Green alga abstraction composition for reducing hyperpiesis and preparation |
| 02/18/2009 | CN101366692A Stable Exenatide formulation |
| 02/18/2009 | CN101366442A Sheep hemoglobin blood pressure reduction peptide and preparation method |
| 02/18/2009 | CN100462438C Chimeric type 5/type 11 or type 35 adenovirus vector for preventing infection with antihuman immunodeficiency virus |
| 02/18/2009 | CN100462437C A fungal immuromodulatory protein produced by microorganisme and uses there of |
| 02/18/2009 | CN100462367C Amidated horseshoe crab anti-endotoxin factor circular analogue peptide molecule, its synthetic method and use |
| 02/18/2009 | CN100462366C Amidated horseshoe crab anti endotoxin factor linear analogue peptide molecule, its synthetic method and use |
| 02/17/2009 | US7491815 Antisense modulation of C-reactive protein expression |
| 02/17/2009 | US7491809 Polynucleotides encoding human cytokine receptor |
| 02/17/2009 | US7491805 Biological conjugates used for drug delivery; side effect reduction |
| 02/17/2009 | US7491801 Identification and development of specific monoclonal antibodies to squamous cell carcinoma |
| 02/17/2009 | US7491800 Cytokine zalpha11 ligand fusion proteins |
| 02/17/2009 | US7491799 Modified botulinum neurotoxins |
| 02/17/2009 | US7491798 Scytovirins and related conjugates, fusion proteins, nucleic acids, vectors, host cells, compositions, antibodies and methods of using scytovirins |
| 02/17/2009 | US7491797 PRO6308 polypeptide |
| 02/17/2009 | US7491796 Retro-inversion peptides that target GIT receptors and related methods |
| 02/17/2009 | US7491795 Neuropeptides and their use for pest control |
| 02/17/2009 | US7491794 Macrocyclic compounds as inhibitors of viral replication |
| 02/17/2009 | US7491705 ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester; ischemic disease, immunologic disease, multiple sclerosis, Alzheimer's disease, osteoporosis, diseases caused by brain tissue damage, cataract, glaucoma |
| 02/17/2009 | US7491704 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents |
| 02/17/2009 | US7491703 Tetrapeptide regulating blood glucose level in diabetes mellitus |
| 02/17/2009 | US7491702 X1-Ser-Met-Arg-Glu-Arg-X2 in which X1 and X2 are up to 30 amino acid residues and the formula represents a reverse-order sequence corresponding to amino acid residues 332 to 328 of human APP and from zero to 30 successive amino acid residues |
| 02/17/2009 | US7491701 Peptides that bind to HSP90 proteins |
| 02/17/2009 | US7491700 Contacting a cell with a peptide compound capable of inducing a conformational change in Bcl-2; converting the Bcl-2 into a pro-apoptotic form |
| 02/17/2009 | US7491699 Peptide nanostructures and methods of generating and using the same |
| 02/17/2009 | US7491698 Mixing and matching TC proteins for pest control |
| 02/17/2009 | US7491697 Muteins of fibroblast growth factor 21 |
| 02/17/2009 | US7491696 Proteolysis resistant active VEGF |
| 02/17/2009 | US7491695 Methods of using macrocyclic modulators of the ghrelin receptor |
| 02/17/2009 | US7491694 Dental restorative materials |
| 02/17/2009 | US7491693 Administering High Density Lipoproteins |
| 02/17/2009 | US7491692 admixing a supplement selected from the therapeutically active agents for facilitating axon growth and a flowable carrier component capable of forming a matrix in vivo at a nerve lesion site and the active agent is releasable from the matrix |
| 02/17/2009 | US7491691 Bone and/or cartilage development-stimulating peptide incorporating proline or hydroxyproline; implants |
| 02/17/2009 | US7491690 Self-assembly and mineralization of peptide-amphiphile nanofibers |
| 02/17/2009 | US7491689 Compositions comprising the biologically active peptide YSL |
| 02/17/2009 | US7491550 Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2) |
| 02/17/2009 | US7491537 Nucleic acid formulations for gene delivery and methods of use |
| 02/17/2009 | US7491529 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 02/17/2009 | US7491524 Antisense inhibitors of human RNase III; antisense therapy |
| 02/17/2009 | US7491507 Using lactobacillus to ferment hypotensive agents comprised of milk protein amino acid sequences; treatment for hypertension |
| 02/17/2009 | US7491503 Identification of ligands by selective amplification of cells transfected with receptors |
| 02/17/2009 | US7491501 Methods for identifying modulators of intracellular aggregate formation |
| 02/17/2009 | US7491500 Mammalian cytokine; related reagents |
| 02/17/2009 | US7491490 For inhibition of viral entry into cells |
| 02/17/2009 | US7491410 Food grade transglutaminase inhibitor and uses thereof |
| 02/17/2009 | US7491406 Fast dissolving orally consumable films |
| 02/17/2009 | US7491405 Antigenic protein originating in Malassezia |
| 02/17/2009 | US7491403 containing a sequestration agent including proteins, lipids and carbohydrates, particularly albumin; treating neuromuscular diseases and pain |
| 02/17/2009 | US7491402 Superantigens SMEZ-2, SPE-G, SPE-H and SPE-J and uses thereof |
| 02/17/2009 | US7491401 Lawsonia intracellularis vaccine |
| 02/17/2009 | US7491398 Proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| 02/17/2009 | US7491397 Receptor binding polypeptides |
| 02/17/2009 | US7491396 peptides; reduced allergenic activity as compared to Phl p 2 wild type; vaccine; biodrug |
| 02/17/2009 | US7491394 Using copper binding protein as therapeutic tool in prevention of viral infection and treatment of cell proliferative disorders |
| 02/17/2009 | US7491389 Bone marrow; controlling cell differentiation |
| 02/17/2009 | US7491386 lactic bacteria strain dairy in origin, may administer in an edible composition, adheres to tooth surface and produces growth inhibition factor |
| 02/17/2009 | US7491384 administering enothelial growth factors with delivery vehicle (powdered bone, tricalcium phosphate, hydroxyapatite, polymethacrylate, biodegradable polyester, aqueous polymeric gel, or fibrin sealant) |